Key result
Isolated St Jude mitral valve replacement demonstrates ~63% overall survival at nineteen years.
Cohort (n=440)
The St Jude Medical prosthesis demonstrates excellent very-long-term durability in the mitral position, though managing long-term anticoagulation remains challenging.
Answers are grounded in this paper and cite their sources.
Supports long-term durability expectations for St Jude mitral prosthesis; extends observational data but leaves randomized comparisons open.
BACKGROUND: In this retrospective study, approximately 440 patients received mitral valve replacements with the St Jude Medical prosthesis. The last patient was operated on 10 years before the beginning of the follow-up. The extended follow-up was 19 years. METHODS AND RESULTS: Four hundred forty patients (sex ratio, 1.32 [men to women]; age, 60+/-11.4 years; age range, 7 to 75 years) were operated on from 1979 to 1987. All patients underwent isolated mitral valve replacement. Tricuspid plasty was the only associated procedure. The follow-up at 19 years was 98% complete. The overall actuarial survival rate was 63+/-3.3% at 19 years, and the actuarial survival rate (only valve related) was 83+/-2.7%. The operative mortality rate (0 to 30 days) was 4.09%. We found that 89.4% of the patients alive at 19 years were in NYHA class I/II. Multivariate analysis showed that age and sex were significantly correlated with valve-related mortality and that age, sex, NYHA class, and atrial fibrillation were significantly correlated with overall mortality. The linearized rates (percent patient-years) of thromboembolism, thrombosis, and hemorrhage were 0.69, 0.2, and 1, respectively. At 19 years, freedom from endocarditis and reoperation was 98.6+/-1% and 90+/-3%, respectively. CONCLUSIONS: In this study, the very-long-term results confirm the excellent durability of the St Jude Medical prosthesis in the mitral position and show the difficulty of adjusting the anticoagulation protocol, even after long-term treatment.
No takes yet. Share an insight, caveat, or question.
Remadi et al. (2001) conducted a cohort in Mitral valve disease requiring replacement (n=440). St Jude Medical prosthesis was evaluated on Overall actuarial survival rate at 19 years. Isolated mitral valve replacement with the St Jude Medical prosthesis demonstrated an overall actuarial survival rate of 63% and a valve-related survival rate of 83% at 19 years.
Synapse has enriched 10 related papers. Consider them for comparative context: